Amplio Strategies launches its new training journey
MONTREAL, June 1, 2022 /CNW Telbec/ – Amplio Stratégies is proud to launch its new 8-theme Mental Health in the Workplace training journey, which focuses on the physical health and well-being of all players in an organization. Stress management, physical activity, meditation, posture and sleep are just a few of the topics covered in this journey, launched as part of National Physical Health Day, scheduled for June 5.
“Recognizing the importance of a healthy organizational culture, businesses are more interested than ever in supporting employees through concrete strategies, including skills development, to maintain the overall health of their resources.”said Philippe Richard Bertrand, Partner and Head of Revenue at Amplio Stratégies.
Dynamic capsules, passionate experts
Moderated by experts Shawn Belliveau, osteopath and kinesiologist, and Catherine Therrien, doctor of chiropractic, the capsules are about 2 to 5 minutes each and offer tips useful techniques and tips to deepen thinking, promote workplace wellness, put into action and integrate best practices into their daily lives.
“The pandemic, the reorganization of methods and telework have had many negative impacts on workers. Less physically active employees are often more likely to experience adverse effects, experience more stress, and be absent more often. On the other hand, a more active workforce will be more motivated, more productive and more committed to its employer,” adds Shawn Belliveau, D.O., B.Sc., CFMP, PNL and director of the Centre Santé Holistique Pilates et Plus clinic.
Find out more about Taking Care of Your Physical Health in the Workplace here: https://formations-amplio.illuxi.com/taking-care-of-physical-health-workplace
About Amplio Stratégies
Support, Innovate, Teach.
Amplio Stratégies is an agile consulting firm founded in 2016 that supports organizations, leaders and their teams in their transformation challenges and organizational development. Amplio Stratégies offers an integrated offering of training, individual coaching, group coaching, conferences by the team of consultants, trainers and coaches.
SOURCE Amplio Stratégies Inc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2022/01/c4747.html
What happened Shares of Novavax (NASDAQ: NVAX) were jumping 3.1% as of 10:01 a.m. ET on Wednesday after rising as much as 11.3% earlier in the day. The move came after a U.S. Food and Drug Administration (FDA) advisory committee voted 21-0 with one abstention on Tuesday in favor of recommending Emergency Use Authorization (EUA) for Novavax's COVID-19 vaccine NVX-CoV2373.
Yahoo Finance's Anjalee Khemlani joins the Live show to detail Novavax's FDA approval for its two-dose COVID vaccine for adults.
Shares of Veru (NASDAQ: VERU) surged 16.8% on Tuesday, after the biopharmaceutical company submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for its novel coronavirus oral drug candidate, sabizabulin. Sabizabulin is a once-daily antiviral and anti-inflammatory treatment for hospitalized patients with moderate to severe COVID-19, who are at high risk of acute respiratory distress syndrome. "COVID-19 new cases and hospitalizations are on the rise again with a summer and fall-winter peaks expected," Veru CEO Mitchell Steiner said in a press release.
An FDA panel voted nearly unanimously in favor of Novavax's Covid shot on Tuesday. And, in after-hours trading, NVAX stock surged.
The ability to diagnose cancers with specific genetic alterations offers new hope for developing targeted treatment options for patients. For example, an estimated 22% of all solid-tumor cancers harbor a mutation in the KRAS gene. While there are multiple types of KRAS mutations, Amgen made history in 2021 by earning the first approval for this high-value target that was once considered "undruggable."
At long last, Novavax (NVAX) may be close to getting its EUA. As the company announced late Tuesday, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) just voted 21-0 (with one abstention) to recommend that the FDA grant Novavax's "Nuvaxovid" coronavirus vaccine (aka NVX-CoV2373) Emergency Use Authorization (EUA) to protect patients aged 18 and older from getting infected with Covid-19. If the FDA agrees with the recommendation, and
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT ASCO Abstract and Poster In late April of this year, CEL-SCI Corporation (NYSE:CVM) emerged from its cocoon and announced that multiple abstracts had been accepted by American Society of Clinical Oncology (ASCO) for presentation during the organization’s 2022 meeting from June 3 to 7 in Chicago, IL. On June sixth CEL-SCI
The stock tumbled about 20% on Friday after the heath regulator's reviewers flagged concerns of a type of heart inflammation following the vaccination, adding uncertainty over the outcome of Tuesday's meeting. However, the voting by the outside advisers – 21 for, none against and 1 abstention – indicates that the FDA could soon authorize the fourth vaccine in the United States, where Novavax hopes it would become the shot of choice among vaccine skeptics. The positive vote "acknowledges the strength of our data and the importance of a protein-based Covid-19 vaccine", Novavax Chief Executive Officer Stanley Erck said on Tuesday.
In this article, we discuss the 10 stocks to buy before the next pandemic. If you wish to skip our comprehensive review of the biotech firms well-positioned to fight the next pandemic, go directly to 5 Stocks to Buy Before the Next Pandemic. The Covid-19 pandemic tested the world’s readiness to deal with a global health […]
(Bloomberg) — Novavax Inc. shares rose after an advisory panel recommended US approval of the company’s coronavirus vaccine, though the rally will barely make dent in the 85% loss shareholders have endured from the 2021 peak.Most Read from BloombergTarget Tries to Save Itself by Putting Everything on SaleAmazon’s Stock Split Delivers More Than Bargained ForTarget's Oversupply Problem Should Scare All RetailersApple Products Set to Use Common Charging Point After EU DealThese Are the World’s 20
The BA.4 and BA.5 subvariants of the highly transmissible omicron variant of the coronavirus that causes COVID-19 are spreading rapidly, according to data from the Centers for Disease Control and Prevention, and may overtake others to dominate in the U.S.
FDA votes to recommend use of Novavax COVID-19 vaccine in adults
Risk of heart inflammation from mRNA vaccines is being studied, creator says.
Over the last two years, it's become clearer and clearer that the path of the COVID pandemic is anything but certain. In the first six months of 2022, the U.S. has experienced both a record high for new daily cases as well as a decline in infections so significant that officials lifted nearly every restriction. Despite cases rising rather notably in May, they're now on the decline once more—it can be a challenge to keep up. According to the Centers for Disease Control and Prevention (CDC), there
Newcomer Arcellx could rival Johnson & Johnson in multiple myeloma, an analyst said as the biotech popped to a two-month high.
"I bawled my eyes out when I left there."View Entire Post ›
Shares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising — test results for a lung cancer treatment.
“Several factors likely affect crude case rates.”
After backpacking around Morocco, a U.S. traveler was left stunned by a Moroccan hospital bill that he received on the last day.
Shares of Sabra Health Care REIT (NASDAQ: SBRA) surged 20.2% in May, according to data provided by S&P Global Market Intelligence. The healthcare-focused real estate investment trust (REIT) reported its first-quarter results and completed a large-scale acquisition last month. Sabra Health Care REIT reported solid first-quarter results in May. The healthcare REIT continued to collect rent despite the lingering impacts of the pandemic.

source